Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Cellulite treatment
View:
Post by LakeOromocto on Jan 30, 2024 3:21am

Cellulite treatment

Human trial planned this year! 400,000 euros
Comment by forhandlaren on Jan 30, 2024 6:24am
Something tells me that I won't regret my 50 percent investment increase lately. I like the transparency that Atheln has brought to the table. The anti-cellulite clinical trial was a great bonus!
Comment by PeterG on Jan 30, 2024 8:07am
Where do you know that Atheln is in the game here? My understanding is that they were only engaged for prepping the Bio exhibition last year ?? 
Comment by forhandlaren on Jan 30, 2024 9:16am
That's an educated guess since the company does not have the capability in-house to establish the new strategic direction. Pretty sure that Atheln still hangs around, if not, someone else has provided the knowledge. "Following the conclusion of the BIO conference, Sirona will continue to work with Atheln to extend its global outreach to companies that did not attend the event. By ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities